Guidelines of care for the management of basal cell carcinoma

Journal of the American Academy of Dermatology

Volumn 78, Issue 3, 2018, Pages 540-559

  Bichakjian, Christopher ^a   Armstrong, April ^b   Baum, Christian ^c   Bordeaux, Jeremy S ^d   Brown, Marc ^e   Busam, Klaus J ^f   Eisen, Daniel B ^g   Iyengar, Vivek ^h   Lober, Clifford ⁱ   Margolis, David J ^j   Messina, Jane ^k,l   Miller, Alexander ^m   Miller, Stanley ⁿ   Mostow, Eliot ^o   Mowad, Christen ^p   Nehal, Kishwer ^f   Schmitt Burr, Kristi ^q   Sekulic, Aleksandar ^r   Storrs, Paul ^h   Teng, Joyce ^s   Yu, Siegrid ^t   Huang, Conway ^u   Boyer, Kevin ^v   Begolka, Wendy Smith ^v   Alam, Murad ^w   Kim, John Y S ^x   Kozlow, Jeffrey H ^a   Mittal, Bharat ^w   Moyer, Jeffrey ^a   Olencki, Thomas ^y   Rodgers, Phillip ^a   more..

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c MAYO CLINIC   (United States)

^d CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF ROCHESTER   (United States)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h Private Practice   (United States)

ⁱ Private Practice   (United States)

^j UNIVERSITY OF PENNSYLVANIA   (United States)

^k UNIVERSITY OF SOUTH FLORIDA   (United States)

^l H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^m Private Practice   (United States)

ⁿ Private Practice   (United States)

^o NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

^p Geisinger Medical Center   (United States)

^q Basal Cell Carcinoma Nevus Syndrome Life Support Network   (United States)

^r MAYO CLINIC   (United States)

^s STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^t UNIVERSITY OF CALIFORNIA   (United States)

^u UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^v AMERICAN ACADEMY OF DERMATOLOGY   (United States)

^w NORTHWESTERN UNIVERSITY   (United States)

^x NORTHWESTERN UNIVERSITY   (United States)

^y OHIO STATE UNIVERSITY   (United States)

more..

Author keywords

basal cell carcinoma; biopsy; curettage; metastasis; phototherapy; radiotherapy; staging; surgery; surveillance; topical therapy

Indexed keywords

IMIQUIMOD; AMINOQUINOLINE DERIVATIVE; ANILIDE; ANTINEOPLASTIC AGENT; PHOTOSENSITIZING AGENT; PYRIDINE DERIVATIVE; VISMODEGIB;

ADVANCED CANCER; ARTICLE; BASAL CELL CARCINOMA; BIOPSY TECHNIQUE; CANCER DIAGNOSIS; CANCER GRADING; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER RISK; CANCER STAGING; COMPARATIVE EFFECTIVENESS; CONSERVATIVE TREATMENT; CRYOSURGERY; EVIDENCE BASED PRACTICE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; LOW LEVEL LASER THERAPY; MOHS MICROGRAPHIC SURGERY; MULTIMODALITY CANCER THERAPY; PHOTODYNAMIC THERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECURRENT DISEASE; SURGICAL TECHNIQUE; SYSTEMIC THERAPY; TOPICAL TREATMENT; CUTANEOUS DRUG ADMINISTRATION; EARLY CANCER DIAGNOSIS; PATHOLOGY; PHOTOCHEMOTHERAPY; RADIOTHERAPY; SECOND CANCER; SECONDARY; SKIN SURGERY; SKIN TUMOR; UNITED STATES;

ADMINISTRATION, CUTANEOUS; AMINOQUINOLINES; ANILIDES; ANTINEOPLASTIC AGENTS; CARCINOMA, BASAL CELL; DERMATOLOGIC SURGICAL PROCEDURES; EARLY DETECTION OF CANCER; HUMANS; NEOPLASM GRADING; NEOPLASM STAGING; NEOPLASMS, SECOND PRIMARY; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PYRIDINES; RADIOTHERAPY; SKIN NEOPLASMS; UNITED STATES;

EID: 85047730231     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2017.10.006     Document Type: Article

References (141)

1. Alam, M., Armstrong, A., Baum, C., et al. Guidelines of care for the management of squamous cell carcinoma. J Am Acad Dermatol 78 (2018), 560–578.
2. National Comprehensive Cancer Center. NCCN Clinical practice guidelines in oncology; basal cell skin cancer. Available at: www.nccn.org. Accessed April 1, 2015.
3. National Comprehensive Cancer Center. NCCN clinical practice guidelines in oncology; basal cell carcinoma (V1.2017). Available at: www.nccn.org. Accessed October 3, 2016.
4. Telfer, N.R., Colver, G.B., Morton, C.A., British Association of Dermatology. Guidelines for the management of basal cell carcinoma. Br J Dermatol 159:1 (2008), 35–48.
5. Ebell, M.H., Siwek, J., Weiss, B.D., et al. Strength of recommendation taxonomy (SORT): a patient-centered approach to grading evidence in the medical literature. J Am Board Fam Pract 17:1 (2004), 59–67.
6. American Academy of Dermatology. Administrative regulations; evidence based clinical practice guidelines. Available at: www.aad.org/Forms/Policies/Uploads/AR/AR%20-%20Evidence-Based%20Clinical%20Guideline.pdf. Accessed December 1, 2014.
7. Rogers, H.W., Weinstock, M.A., Feldman, S.R., Coldiron, B.M., Incidence estimate of nonmelanoma skin cancer (keratinocyte carcinomas) in the U.S. population, 2012. JAMA Dermatol 151:10 (2015), 1081–1086.
8. Linos, E., Schroeder, S.A., Chren, M.M., Potential overdiagnosis of basal cell carcinoma in older patients with limited life expectancy. JAMA 312:10 (2014), 997–998.
9. Fosko, S.W., Counterpoint: limited life expectancy, basal cell carcinoma, health care today, and unintended consequences. J Am Acad Dermatol 73:1 (2015), 162–164.
10. Edge, S.B., American Joint Committee on Cancer, American Cancer Society. AJCC Cancer Staging Handbook: From the AJCC Cancer Staging Manual. 7th ed., 2010, Springer, New York, NY.
11. Roozeboom, M.H., Mosterd, K., Winnepenninckx, V.J., Nelemans, P.J., Kelleners-Smeets, N.W., Agreement between histological subtype on punch biopsy and surgical excision in primary basal cell carcinoma. J Eur Acad Dermatol Venereol 27:7 (2013), 894–898.
12. Haws, A.L., Rojano, R., Tahan, S.R., Phung, T.L., Accuracy of biopsy sampling for subtyping basal cell carcinoma. J Am Acad Dermatol 66:1 (2012), 106–111.
13. Mosterd, K., Thissen, M.R., van Marion, A.M., et al. Correlation between histologic findings on punch biopsy specimens and subsequent excision specimens in recurrent basal cell carcinoma. J Am Acad Dermatol 64:2 (2011), 323–327.
14. Smith, L.C., Cox, N.H., Dawn, G., Shave biopsy without local anaesthetic to diagnose basal cell carcinoma and other skin tumours prior to definitive treatment: analysis of 109 lesions. Br J Dermatol 160:1 (2009), 180–182.
15. Russell, E.B., Carrington, P.R., Smoller, B.R., Basal cell carcinoma: a comparison of shave biopsy versus punch biopsy techniques in subtype diagnosis. J Am Acad Dermatol 41:1 (1999), 69–71.
16. Kadouch, D.J., van Haersma de With, A., Limpens, J., et al. Is a punch biopsy reliable in subtyping basal cell carcinoma? A systematic review. Br J Dermatol 175:2 (2016), 401–403.
17. Codazzi, D., Van Der Velden, J., Carminati, M., et al. Positive compared with negative margins in a single-centre retrospective study on 3957 consecutive excisions of basal cell carcinomas. Associated risk factors and preferred surgical management. J Plast Surg Hand Surg 48:1 (2014), 38–43.
18. Kumar, P., Watson, S., Brain, A.N., et al. Incomplete excision of basal cell carcinoma: a prospective multicentre audit. Br J Plast Surg 55:8 (2002), 616–622.
19. Farhi, D., Dupin, N., Palangie, A., Carlotti, A., Avril, M.F., Incomplete excision of basal cell carcinoma: rate and associated factors among 362 consecutive cases. Dermatol Surg 33:10 (2007), 1207–1214.
20. Hansen, C., Wilkinson, D., Hansen, M., Soyer, H.P., Factors contributing to incomplete excision of nonmelanoma skin cancer by Australian general practitioners. Arch Dermatol 145:11 (2009), 1253–1260.
21. Khan, L., Breen, D., Zhang, L., et al. Predictors of recurrence after radiotherapy for non-melanoma skin cancer. Curr Oncol 21:2 (2014), e326–329.
22. Silverman, M.K., Kopf, A.W., Bart, R.S., Grin, C.M., Levenstein, M.S., Recurrence rates of treated basal cell carcinomas. Part 3: surgical excision. J Dermatol Surg Oncol 18:6 (1992), 471–476.
23. Silverman, M.K., Kopf, A.W., Gladstein, A.H., Bart, R.S., Grin, C.M., Levenstein, M.J., Recurrence rates of treated basal cell carcinomas. Part 4: x-ray therapy. J Dermatol Surg Oncol 18:7 (1992), 549–554.
24. Silverman, M.K., Kopf, A.W., Grin, C.M., Bart, R.S., Levenstein, M.J., Recurrence rates of treated basal cell carcinomas. Part 2: curettage-electrodesiccation. J Dermatol Surg Oncol 17:9 (1991), 720–726.
25. Talbot, S., Hitchcock, B., Incomplete primary excision of cutaneous basal and squamous cell carcinomas in the Bay of Plenty. N Z Med J, 117(1192), 2004, U848.
26. Rieger, K.E., Linos, E., Egbert, B.M., Swetter, S.M., Recurrence rates associated with incompletely excised low-risk nonmelanoma skin cancer. J Cutan Pathol 37:1 (2010), 59–67.
27. Lott, D.G., Manz, R., Koch, C., Lorenz, R.R., Aggressive behavior of nonmelanotic skin cancers in solid organ transplant recipients. Transplantation 90:6 (2010), 683–687.
28. Connolly, S.M., Baker, D.R., Coldiron, B.M., et al., Ad Hoc Task Force. AAD/ACMS/ASDSA/ASMS 2012 appropriate use criteria for Mohs micrographic surgery: a report of the American Academy of Dermatology, American College of Mohs Surgery, American Society for Dermatologic Surgery Association, and the American Society for Mohs Surgery. J Am Acad Dermatol 67:4 (2012), 531–550.
29. Cho, M., Lee, J., James, C.L., Marshman, G., Huilgol, S.C., Scalp basal cell carcinoma: review of 2,202 cases. Dermatol Surg 42:7 (2016), 834–841.
30. Niazi, Z.B., Lamberty, B.G., Perineural infiltration in basal cell carcinomas. Br J Plast Surg 46:2 (1993), 156–157.
31. Chren, M.M., Sahay, A.P., Bertenthal, D.S., Sen, S., Landefeld, C.S., Quality-of-life outcomes of treatments for cutaneous basal cell carcinoma and squamous cell carcinoma. J Invest Dermatol 127:6 (2007), 1351–1357.
32. van Loo, E., Mosterd, K., Krekels, G.A., et al. Surgical excision versus Mohs’ micrographic surgery for basal cell carcinoma of the face: a randomised clinical trial with 10 year follow-up. Eur J Cancer 50:17 (2014), 3011–3020.
33. Smeets, N.W., Krekels, G.A., Ostertag, J.U., et al. Surgical excision vs Mohs’ micrographic surgery for basal-cell carcinoma of the face: randomised controlled trial. Lancet 364:9447 (2004), 1766–1772.
34. Avril, M.F., Auperin, A., Margulis, A., et al. Basal cell carcinoma of the face: surgery or radiotherapy? Results of a randomized study. Br J Cancer 76:1 (1997), 100–106.
35. Rhodes, L.E., de Rie, M.A., Leifsdottir, R., et al. Five-year follow-up of a randomized, prospective trial of topical methyl aminolevulinate photodynamic therapy vs surgery for nodular basal cell carcinoma. Arch Dermatol 143:9 (2007), 1131–1136.
36. Kuijpers, D.I., Thissen, M.R., Berretty, P.J., Ideler, F.H., Nelemans, P.J., Neumann, M.H., Surgical excision versus curettage plus cryosurgery in the treatment of basal cell carcinoma. Dermatol Surg 33:5 (2007), 579–587.
37. Szeimies, R.M., Ibbotson, S., Murrell, D.F., et al. A clinical study comparing methyl aminolevulinate photodynamic therapy and surgery in small superficial basal cell carcinoma (8-20 mm), with a 12-month follow-up. J Eur Acad Dermatol Venereol 22:11 (2008), 1302–1311.
38. Roozeboom, M.H., Aardoom, M.A., Nelemans, P.J., et al. Fractionated 5-aminolevulinic acid photodynamic therapy after partial debulking versus surgical excision for nodular basal cell carcinoma: a randomized controlled trial with at least 5-year follow-up. J Am Acad Dermatol 69:2 (2013), 280–287.
39. Bath-Hextall, F., Ozolins, M., Armstrong, S.J., et al. Surgical excision versus imiquimod 5% cream for nodular and superficial basal-cell carcinoma (SINS): a multicentre, non-inferiority, randomised controlled trial. Lancet Oncol 15:1 (2014), 96–105.
40. Gulleth, Y., Goldberg, N., Silverman, R.P., Gastman, B.R., What is the best surgical margin for a basal cell carcinoma: a meta-analysis of the literature. Plast Reconstr Surg 126:4 (2010), 1222–1231.
41. Thissen, M.R., Nieman, F.H., Ideler, A.H., Berretty, P.J., Neumann, H.A., Cosmetic results of cryosurgery versus surgical excision for primary uncomplicated basal cell carcinomas of the head and neck. Dermatol Surg 26:8 (2000), 759–764.
42. Rowe, D.E., Carroll, R.J., Day, C.L. Jr., Long-term recurrence rates in previously untreated (primary) basal cell carcinoma: implications for patient follow-up. J Dermatol Surg Oncol 15:3 (1989), 315–328.
43. Rowe, D.E., Carroll, R.J., Day, C.L. Jr., Mohs surgery is the treatment of choice for recurrent (previously treated) basal cell carcinoma. J Dermatol Surg Oncol 15:4 (1989), 424–431.
44. Rodriguez-Vigil, T., Vazquez-Lopez, F., Perez-Oliva, N., Recurrence rates of primary basal cell carcinoma in facial risk areas treated with curettage and electrodesiccation. J Am Acad Dermatol 56:1 (2007), 91–95.
45. Spencer, J.M., Pilot study of imiquimod 5% cream as adjunctive therapy to curettage and electrodesiccation for nodular basal cell carcinoma. Dermatol Surg 32:1 (2006), 63–69.
46. Bath-Hextall, F.J., Perkins, W., Bong, J., Williams, H.C., Interventions for basal cell carcinoma of the skin. Cochrane Database Syst Rev(1), 2007, CD003412.
47. Mosterd, K., Thissen, M.R., Nelemans, P., et al. Fractionated 5-aminolaevulinic acid-photodynamic therapy vs. surgical excision in the treatment of nodular basal cell carcinoma: results of a randomized controlled trial. Br J Dermatol 159:4 (2008), 864–870.
48. Unlu, R.E., Altun, S., Kerem, M., Koc, M.N., Is it really necessary to make wide excisions for basal cell carcinoma treatment?. J Craniofac Surg 20:6 (2009), 1989–1991.
49. Mosterd, K., Krekels, G.A., Nieman, F.H., et al. Surgical excision versus Mohs’ micrographic surgery for primary and recurrent basal-cell carcinoma of the face: a prospective randomised controlled trial with 5-years’ follow-up. Lancet Oncol 9:12 (2008), 1149–1156.
50. Muller, F.M., Dawe, R.S., Moseley, H., Fleming, C.J., Randomized comparison of Mohs micrographic surgery and surgical excision for small nodular basal cell carcinoma: tissue-sparing outcome. Dermatol Surg 35:9 (2009), 1349–1354.
51. Mohs, F.E., Chemosurgery: a microscopically controlled method of cancer excision. Arch Surg 42:2 (1941), 279–295.
52. Mohs, F.E., Chemosurgical treatment of cancer of the nose; a microscopically controlled method. Arch Surg 53 (1946), 327–344.
53. Tromovitch, T.A., Stegeman, S.J., Microscopically controlled excision of skin tumors. Arch Dermatol 110:2 (1974), 231–232.
54. Tromovitch, T.A., Stegman, S.J., Microscopie-controlled excision of cutaneous tumors: chemosurgery, fresh tissue technique. Cancer 41:2 (1978), 653–658.
55. Ebede, T.L., Lee, E.H., Dusza, S.W., Busam, K.J., Nehal, K.S., Clinical value of paraffin sections in association with Mohs micrographic surgery for nonmelanoma skin cancers. Dermatol Surg 38:10 (2012), 1631–1638.
56. American Academy of Dermatology. Appropriate uses of paraffin sections in association with Mohs micrographic surgery. 2014 Available at: https://www.aad.org/Forms/Policies/Uploads/PS/PS%20Appropriate%20Uses%20of%20Paraffin%20Sections%20in%20Association%20with%20Mohs%20Mircographic%20Surgery.pdf. (Accessed 1 February 2017)
57. Knox, J.M., Lyles, T.W., Shapiro, E.M., Martin, R.D., Curettage and electrodesiccation in the treatment of skin cancer. Arch Dermatol 82 (1960), 197–204.
58. Salasche, S.J., Curettage and electrodesiccation in the treatment of midfacial basal cell epithelioma. J Am Acad Dermatol 8:4 (1983), 496–503.
59. Goldman, G., The current status of curettage and electrodesiccation. Dermatol Clin 20:3 (2002), 569–578 ix.
60. Basset-Seguin, N., Ibbotson, S.H., Emtestam, L., et al. Topical methyl aminolaevulinate photodynamic therapy versus cryotherapy for superficial basal cell carcinoma: a 5 year randomized trial. Eur J Dermatol 18:5 (2008), 547–553.
61. Wang, I., Bendsoe, N., Klinteberg, C.A., et al. Photodynamic therapy vs. cryosurgery of basal cell carcinomas: results of a phase III clinical trial. Br J Dermatol 144:4 (2001), 832–840.
62. Hall, V.L., Leppard, B.J., McGill, J., Kesseler, M.E., White, J.E., Goodwin, P., Treatment of basal-cell carcinoma: comparison of radiotherapy and cryotherapy. Clin Radiol 37:1 (1986), 33–34.
63. Mallon, E., Dawber, R., Cryosurgery in the treatment of basal cell carcinoma. Assessment of one and two freeze-thaw cycle schedules. Dermatol Surg 22:10 (1996), 854–858.
64. Arits, A.H., Mosterd, K., Essers, B.A., et al. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial. Lancet Oncol 14:7 (2013), 647–654.
65. Ezughah, F.I., Dawe, R.S., Ibbotson, S.H., Fleming, C.J., A randomized parallel study to assess the safety and efficacy of two different dosing regimens of 5% imiquimod in the treatment of superficial basal cell carcinoma. J Dermatolog Treat 19:2 (2008), 111–117.
66. Eigentler, T.K., Kamin, A., Weide, B.M., et al. A phase III, randomized, open label study to evaluate the safety and efficacy of imiquimod 5% cream applied thrice weekly for 8 and 12 weeks in the treatment of low-risk nodular basal cell carcinoma. J Am Acad Dermatol 57:4 (2007), 616–621.
67. Schulze, H.J., Cribier, B., Requena, L., et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe. Br J Dermatol 152:5 (2005), 939–947.
68. Geisse, J., Caro, I., Lindholm, J., Golitz, L., Stampone, P., Owens, M., Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol 50:5 (2004), 722–733.
69. Geisse, J.K., Rich, P., Pandya, A., et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a double-blind, randomized, vehicle-controlled study. J Am Acad Dermatol 47:3 (2002), 390–398.
70. Sterry, W., Ruzicka, T., Herrera, E., et al. Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion. Br J Dermatol 147:6 (2002), 1227–1236.
71. Marks, R., Gebauer, K., Shumack, S., et al. Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose-response trial. J Am Acad Dermatol 44:5 (2001), 807–813.
72. Shumack, S., Robinson, J., Kossard, S., et al. Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens. Arch Dermatol 138:9 (2002), 1165–1171.
73. Beutner, K.R., Geisse, J.K., Helman, D., Fox, T.L., Ginkel, A., Owens, M.L., Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. J Am Acad Dermatol 41:6 (1999), 1002–1007.
74. Roozeboom, M.H., Arits, A.H., Nelemans, P.J., Kelleners-Smeets, N.W., Overall treatment success after treatment of primary superficial basal cell carcinoma: a systematic review and meta-analysis of randomized and nonrandomized trials. Br J Dermatol 167:4 (2012), 733–756.
75. Love, W.E., Bernhard, J.D., Bordeaux, J.S., Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: a systematic review. Arch Dermatol 145:12 (2009), 1431–1438.
76. Roozeboom, M.H., Arits, A.H., Mosterd, K., et al. Three-year follow-up results of photodynamic therapy vs. imiquimod vs. fluorouracil for treatment of superficial basal cell carcinoma: a single-blind, noninferiority, randomized controlled trial. J Invest Dermatol 136:8 (2016), 1568–1574.
77. Kuijpers, D.I., Thissen, M.R., Thissen, C.A., Neumann, M.H., Similar effectiveness of methyl aminolevulinate and 5-aminolevulinate in topical photodynamic therapy for nodular basal cell carcinoma. J Drugs Dermatol 5:7 (2006), 642–645.
78. Romagosa, R., Saap, L., Givens, M., et al. A pilot study to evaluate the treatment of basal cell carcinoma with 5-fluorouracil using phosphatidyl choline as a transepidermal carrier. Dermatol Surg 26:4 (2000), 338–340.
79. Miller, B.H., Shavin, J.S., Cognetta, A., et al. Nonsurgical treatment of basal cell carcinomas with intralesional 5-fluorouracil/epinephrine injectable gel. J Am Acad Dermatol 36:1 (1997), 72–77.
80. Soler, A.M., Angell-Petersen, E., Warloe, T., et al. Photodynamic therapy of superficial basal cell carcinoma with 5-aminolevulinic acid with dimethylsulfoxide and ethylendiaminetetraacetic acid: a comparison of two light sources. Photochem Photobiol 71:6 (2000), 724–729.
81. Osiecka, B., Jurczyszyn, K., Ziolkowski, P., The application of Levulan-based photodynamic therapy with imiquimod in the treatment of recurrent basal cell carcinoma. Med Sci Monit 18:2 (2012), PI5–PI9.
82. de Vijlder, H.C., Sterenborg, H.J., Neumann, H.A., Robinson, D.J., de Haas, E.R., Light fractionation significantly improves the response of superficial basal cell carcinoma to aminolaevulinic acid photodynamic therapy: five-year follow-up of a randomized, prospective trial. Acta Derm Venereol 92:6 (2012), 641–647.
83. Schleier, P., Berndt, A., Kolossa, S., Zenk, W., Hyckel, P., Schultze-Mosgau, S., Comparison of aminolevulinic acid (ALA)-thermogel-PDT with methyl-ALA-thermogel-PDT in basal cell carcinoma. Photodiagnosis Photodyn Ther 4:3 (2007), 197–201.
84. Apalla, Z., Sotiriou, E., Chovarda, E., Lefaki, I., Devliotou-Panagiotidou, D., Ioannides, D., Skin cancer: preventive photodynamic therapy in patients with face and scalp cancerization. A randomized placebo-controlled study. Br J Dermatol 162:1 (2010), 171–175.
85. Jambusaria-Pahlajani, A., Kanetsky, P.A., Karia, P.S., et al. Evaluation of AJCC tumor staging for cutaneous squamous cell carcinoma and a proposed alternative tumor staging system. JAMA Dermatol 149:4 (2013), 402–410.
86. Wang, H., Xu, Y., Shi, J., Gao, X., Geng, L., Photodynamic therapy in the treatment of basal cell carcinoma: a systematic review and meta-analysis. Photodermatol Photoimmunol Photomed 31:1 (2015), 44–53.
87. Foley, P., Freeman, M., Menter, A., et al. Photodynamic therapy with methyl aminolevulinate for primary nodular basal cell carcinoma: results of two randomized studies. Int J Dermatol 48:11 (2009), 1236–1245.
88. Ashby, M.A., Smith, J., Ainslie, J., McEwan, L., Treatment of nonmelanoma skin cancer at a large Australian center. Cancer 63:9 (1989), 1863–1871.
89. Cognetta, A.B., Howard, B.M., Heaton, H.P., Stoddard, E.R., Hong, H.G., Green, W.H., Superficial x-ray in the treatment of basal and squamous cell carcinomas: a viable option in select patients. J Am Acad Dermatol 67:6 (2012), 1235–1241.
90. Bhatnagar, A., Nonmelanoma skin cancer treated with electronic brachytherapy: results at 1 year. Brachytherapy 12:2 (2013), 134–140.
91. Paravati, A.J., Hawkins, P.G., Martin, A.N., et al. Clinical and cosmetic outcomes in patients treated with high-dose-rate electronic brachytherapy for nonmelanoma skin cancer. Pract Radiat Oncol 5:6 (2015), e659–664.
92. Ballester-Sanchez, R., Pons-Llanas, O., Candela-Juan, C., et al. Electronic brachytherapy for superficial and nodular basal cell carcinoma: a report of two prospective pilot trials using different doses. J Contemp Brachytherapy 8:1 (2016), 48–55.
93. Smucler, R., Vlk, M., Combination of Er:YAG laser and photodynamic therapy in the treatment of nodular basal cell carcinoma. Lasers Surg Med 40:2 (2008), 153–158.
94. Tran, H.T., Lee, R.A., Oganesyan, G., Jiang, S.B., Single treatment of non-melanoma skin cancers using a pulsed-dye laser with stacked pulses. Lasers Surg Med 44:6 (2012), 459–467.
95. Kulp, J., Levy, S., Fein, M.C., Adams, M., Furst, J., Meng, T.C., Pharmacokinetics of imiquimod 3.75% cream applied daily for 3 weeks to actinic keratoses on the face and/or balding scalp. Arch Dermatol Res 302:7 (2010), 539–544.
96. Roldan-Marin, R., Toussaint-Caire, S., Imiquimod 5% as adjuvant therapy for incompletely excised iInfiltrative nodular basal cell carcinoma and dermoscopy to monitor treatment response. Dermatol Ther (Heidelb) 5:4 (2015), 265–272.
97. Bonilla, R., Solebo, A.L., Khandwala, M.A., Jones, C.A., Imiquimod 5% cream as an adjuvant pre-operative treatment for basal cell carcinoma of the periocular area. Orbit 33:6 (2014), 471–473.
98. Thissen, M.R., Kuijpers, D.I., Krekels, G.A., Local immune modulator (imiquimod 5% cream) as adjuvant treatment after incomplete Mohs micrographic surgery for large, mixed type basal cell carcinoma: a report of 3 cases. J Drugs Dermatol 5:5 (2006), 461–464.
99. Berroeta, L., Clark, C., Dawe, R.S., Ibbotson, S.H., Fleming, C.J., A randomized study of minimal curettage followed by topical photodynamic therapy compared with surgical excision for low-risk nodular basal cell carcinoma. Br J Dermatol 157:2 (2007), 401–403.
100. American Academy of Dermatology. Position statement on superficial radiation therapy for basal cell carcinoma (BCC) and squamous cell carcinomas (SCC). Available at: https://www.aad.org/Forms/Policies/Uploads/PS/PS-Superficial%20Radiation%20Therapy.pdf. Accessed November 5, 2016.
101. American Academy of Dermatology. Position statement on electronic surface brachytherapy for basal cell carcinoma (BCC) and squamous cell carcinomas (SCC). Available at: https://www.aad.org/Forms/Policies/Uploads/PS/PS%20-%20Electronic%20Surface%20Brachytherapy.pdf. Accessed November 5, 2016.
102. Bart, R.S., Kopf, A.W., Gladstein, A.H., Treatment of morphea-type basal cell carcinomas with radiation therapy. Arch Dermatol 113:6 (1977), 783–786.
103. Gauden, R., Pracy, M., Avery, A.M., Hodgetts, I., Gauden, S., HDR brachytherapy for superficial non-melanoma skin cancers. J Med Imaging Radiat Oncol 57:2 (2013), 212–217.
104. Choi, S.H., Kim, K.H., Song, K.H., Er:YAG ablative fractional laser-primed photodynamic therapy with methyl aminolevulinate as an alternative treatment option for patients with thin nodular basal cell carcinoma: 12-month follow-up results of a randomized, prospective, comparative trial. J Eur Acad Dermatol Venereol 30:5 (2016), 783–788.
105. von Domarus, H., Stevens, P.J., Metastatic basal cell carcinoma. Report of five cases and review of 170 cases in the literature. J Am Acad Dermatol 10:6 (1984), 1043–1060.
106. Moeholt, K., Aagaard, H., Pfeiffer, P., Hansen, O., Platinum-based cytotoxic therapy in basal cell carcinoma—a review of the literature. Acta Oncol 35:6 (1996), 677–682.
107. Sekulic, A., Migden, M.R., Oro, A.E., et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med 366:23 (2012), 2171–2179.
108. Sekulic, A., Migden, M.R., Lewis, K., et al. Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC. J Am Acad Dermatol 72:6 (2015), 1021–1026.e1028.
109. Basset-Seguin, N., Hauschild, A., Grob, J.J., et al. Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial. Lancet Oncol 16:6 (2015), 729–736.
110. Migden, M.R., Guminski, A., Gutzmer, R., et al. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. Lancet Oncol 16:6 (2015), 716–728.
111. Dummer, R., Guminski, A., Gutzmer, R., et al. The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): a phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma. J Am Acad Dermatol 75:1 (2016), 113–125.e115.
112. Danial, C., Sarin, K.Y., Oro, A.E., Chang, A.L., An Investigator-initiated open-label trial of sonidegib in advanced basal cell carcinoma patients resistant to vismodegib. Clin Cancer Res 22:6 (2016), 1325–1329.
113. Chang, A.L., Solomon, J.A., Hainsworth, J.D., et al. Expanded access study of patients with advanced basal cell carcinoma treated with the hedgehog pathway inhibitor, vismodegib. J Am Acad Dermatol 70:1 (2014), 60–69.
114. Jacobsen, A.A., Aldahan, A.S., Hughes, O.B., Shah, V.V., Strasswimmer, J., Hedgehog pathway inhibitor therapy for locally advanced and metastatic basal cell carcinoma: a systematic review and pooled analysis of interventional studies. JAMA Dermatol 152:7 (2016), 816–824.
115. Tang, J.Y., Mackay-Wiggan, J.M., Aszterbaum, M., et al. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. N Engl J Med 366:23 (2012), 2180–2188.
116. Wheless, L., Black, J., Alberg, A.J., Nonmelanoma skin cancer and the risk of second primary cancers: a systematic review. Cancer Epidemiol Biomarkers Prev 19:7 (2010), 1686–1695.
117. Wehner, M.R., Linos, E., Parvataneni, R., Stuart, S.E., Boscardin, W.J., Chren, M.M., Timing of subsequent new tumors in patients who present with basal cell carcinoma or cutaneous squamous cell carcinoma. JAMA Dermatol 151:4 (2015), 382–388.
118. Song, F., Qureshi, A.A., Giovannucci, E.L., et al. Risk of a second primary cancer after non-melanoma skin cancer in white men and women: a prospective cohort study. PLoS Med, 10(4), 2013, e1001433.
119. Rees, J.R., Zens, M.S., Gui, J., Celaya, M.O., Riddle, B.L., Karagas, M.R., Non melanoma skin cancer and subsequent cancer risk. PLoS One, 9(6), 2014, e99674.
120. Robinson, J.K., Wayne, J.D., Martini, M.C., Hultgren, B.A., Mallett, K.A., Turrisi, R., Early detection of new melanomas by patients with melanoma and their partners using a structured skin self-examination skills training intervention: a randomized clinical trial. JAMA Dermatol 152:9 (2016), 979–985.
121. van der Pols, J.C., Williams, G.M., Pandeya, N., Logan, V., Green, A.C., Prolonged prevention of squamous cell carcinoma of the skin by regular sunscreen use. Cancer Epidemiol Biomarkers Prev 15:12 (2006), 2546–2548.
122. Green, A., Williams, G., Neale, R., et al. Daily sunscreen application and betacarotene supplementation in prevention of basal-cell and squamous-cell carcinomas of the skin: a randomised controlled trial. Lancet 354:9180 (1999), 723–729.
123. Weinstock, M.A., Bingham, S.F., Digiovanna, J.J., et al. Tretinoin and the prevention of keratinocyte carcinoma (basal and squamous cell carcinoma of the skin): a veterans affairs randomized chemoprevention trial. J Invest Dermatol 132:6 (2012), 1583–1590.
124. Tang, J.Y., Chiou, A.S., Mackay-Wiggan, J.M., et al. Tazarotene: randomized, double-blind, vehicle-controlled, and open-label concurrent trials for basal cell carcinoma prevention and therapy in patients with basal cell nevus syndrome. Cancer Prev Res (Phila) 7:3 (2014), 292–299.
125. Weinstock, M.A., Bingham, S.F., Lew, R.A., et al. Topical tretinoin therapy and all-cause mortality. Arch Dermatol 145:1 (2009), 18–24.
126. Tangrea, J.A., Edwards, B.K., Taylor, P.R., et al. Long-term therapy with low-dose isotretinoin for prevention of basal cell carcinoma: a multicenter clinical trial. Isotretinoin-Basal Cell Carcinoma Study Group. J Natl Cancer Inst 84:5 (1992), 328–332.
127. Levine, N., Moon, T.E., Cartmel, B., et al. Trial of retinol and isotretinoin in skin cancer prevention: a randomized, double-blind, controlled trial. Southwest Skin Cancer Prevention Study Group. Cancer Epidemiol Biomarkers Prev 6:11 (1997), 957–961.
128. Moon, T.E., Levine, N., Cartmel, B., et al. Effect of retinol in preventing squamous cell skin cancer in moderate-risk subjects: a randomized, double-blind, controlled trial. Southwest Skin Cancer Prevention Study Group. Cancer Epidemiol Biomarkers Prev 6:11 (1997), 949–956.
129. Kadakia, K.C., Barton, D.L., Loprinzi, C.L., et al. Randomized controlled trial of acitretin versus placebo in patients at high-risk for basal cell or squamous cell carcinoma of the skin (North Central Cancer Treatment Group Study 969251). Cancer 118:8 (2012), 2128–2137.
130. Chen, A.C., Martin, A.J., Choy, B., et al. A phase 3 randomized trial of nicotinamide for skin-cancer chemoprevention. N Engl J Med 373:17 (2015), 1618–1626.
131. Kreul, S.M., Havighurst, T., Kim, K., et al. A phase III skin cancer chemoprevention study of DFMO: long-term follow-up of skin cancer events and toxicity. Cancer Prev Res (Phila) 5:12 (2012), 1368–1374.
132. Bailey, H.H., Kim, K., Verma, A.K., et al. A randomized, double-blind, placebo-controlled phase 3 skin cancer prevention study of {alpha}-difluoromethylornithine in subjects with previous history of skin cancer. Cancer Prev Res (Phila) 3:1 (2010), 35–47.
133. Elmets, C.A., Viner, J.L., Pentland, A.P., et al. Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial. J Natl Cancer Inst 102:24 (2010), 1835–1844.
134. Tang, J.Y., Aszterbaum, M., Athar, M., et al. Basal cell carcinoma chemoprevention with nonsteroidal anti-inflammatory drugs in genetically predisposed PTCH1+/- humans and mice. Cancer Prev Res (Phila) 3:1 (2010), 25–34.
135. Clark, L.C., Combs, G.F. Jr., Turnbull, B.W., et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA 276:24 (1996), 1957–1963.
136. Duffield-Lillico, A.J., Slate, E.H., Reid, M.E., et al. Selenium supplementation and secondary prevention of nonmelanoma skin cancer in a randomized trial. J Natl Cancer Inst 95:19 (2003), 1477–1481.
137. Greenberg, E.R., Baron, J.A., Stukel, T.A., et al. A clinical trial of beta carotene to prevent basal-cell and squamous-cell cancers of the skin. The Skin Cancer Prevention Study Group. N Engl J Med 323:12 (1990), 789–795.
138. Chen, J., Ruczinski, I., Jorgensen, T.J., et al. Nonmelanoma skin cancer and risk for subsequent malignancy. J Natl Cancer Inst 100:17 (2008), 1215–1222.
139. Marcil, I., Stern, R.S., Risk of developing a subsequent nonmelanoma skin cancer in patients with a history of nonmelanoma skin cancer: a critical review of the literature and meta-analysis. Arch Dermatol 136:12 (2000), 1524–1530.
140. Flohil, S.C., van der Leest, R.J., Arends, L.R., de Vries, E., Nijsten, T., Risk of subsequent cutaneous malignancy in patients with prior keratinocyte carcinoma: a systematic review and meta-analysis. Eur J Cancer 49:10 (2013), 2365–2375.
141. Geng, A., Weinstock, M.A., Hall, R., et al. Tolerability of high-dose topical tretinoin: the Veterans Affairs Topical Tretinoin Chemoprevention Trial. Br J Dermatol 161:4 (2009), 918–924.